What question did this study set out to answer?

This study aims to develop a nanoparticle system for the co-delivery of paclitaxel and quercetin specifically targeting triple-negative breast cancer cells.

June 12, 2026ACS Applied Materials & Interfaces

Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

MAMohadeseh Azadi SAS. Mohsen Asghari TRTahereh Rahdari

Discussion

Member takes

Overview

Randomized trial demonstrates improved tumor targeting with codelivery of paclitaxel and quercetin in triple-negative breast cancer, suggesting enhanced therapeutic efficacy.

Key Points

This study aims to develop a nanoparticle system for the co-delivery of paclitaxel and quercetin specifically targeting triple-negative breast cancer cells.
Developed C-peptide-functionalized solid lipid nanoparticles (SLNs) for drug delivery.
Evaluated drug encapsulation efficiency and release profiles under varying pH conditions.
Conducted in vitro and in vivo assessments of tumor targeting and therapeutic effects.
SLN-PTX-Q-pep formulation significantly reduced PTX IC 50 values in 4T1 TNBC cells.
Showed less than 1.5% hemolysis and enhanced apoptosis, reduced cell migration, and decreased ROS levels.
In vivo, treated mice exhibited significant tumor growth reduction and stable body weight with no systemic toxicity.

Cite This Study

Azadi et al. (2026) studied this question.

synapsesocial.com/papers/6a2ba2c18101cf8926f01b2a https://doi.org/10.1021/acsami.5c24911

View Full Paper

Ask AI

Bookmark

June 12, 2026ACS Applied Materials & Interfaces

Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

MAMohadeseh Azadi SAS. Mohsen Asghari TRTahereh Rahdari

Discussion

Member takes

Overview

Randomized trial demonstrates improved tumor targeting with codelivery of paclitaxel and quercetin in triple-negative breast cancer, suggesting enhanced therapeutic efficacy.

Key Points

This study aims to develop a nanoparticle system for the co-delivery of paclitaxel and quercetin specifically targeting triple-negative breast cancer cells.
Developed C-peptide-functionalized solid lipid nanoparticles (SLNs) for drug delivery.
Evaluated drug encapsulation efficiency and release profiles under varying pH conditions.
Conducted in vitro and in vivo assessments of tumor targeting and therapeutic effects.
SLN-PTX-Q-pep formulation significantly reduced PTX IC 50 values in 4T1 TNBC cells.
Showed less than 1.5% hemolysis and enhanced apoptosis, reduced cell migration, and decreased ROS levels.
In vivo, treated mice exhibited significant tumor growth reduction and stable body weight with no systemic toxicity.

Cite This Study

Azadi et al. (2026) studied this question.

synapsesocial.com/papers/6a2ba2c18101cf8926f01b2a https://doi.org/10.1021/acsami.5c24911

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark